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1.1	Introduction
Research	and	development	of	nanotechnologies	and	manufactured	nanomaterials	is	undergoing	sustained	and	rapid	expansion	with	the	numerous	bespoke	biomedical	applications.	The	processes	that	underpin	nanomedicine
pharmacokinetics	 and	 pharmacodynamics	 are	 not	 as	 fully	 characterised	 as	 for	 conventional	 small	 molecule	 medicines,	 and	 this	 complicates	 the	 development,	 optimisation	 and	 regulatory	 evaluation	 of	 novel	 nanomaterials.
Nanomedicine	strategies	have	emerged	as	advanced	approaches	 to	enhance	drug	delivery	and	 improve	 the	 treatment	of	several	diseases,	 through	either	augmented	drug	absorption,	distribution,	or	 residency	within	 the	systemic
circulation.	Protection	of	the	active	pharmaceutical	ingredient	(API)	from	degradation	can	increase	the	length	of	time	for	which	drugs	are	present	in	the	blood	circulation	and	tissues,	and	coupling	with	active	targeting	ligands	for	cells
or	tissues	is	showing	potential	to	improve	the	therapeutic	index	for	many	APIs.
Solid	drug	nanoparticles	(SDNs)	are	predominantly	composed	of	the	API	itself,	whereby	the	drug	particle	surface	is	stabilised	using	surfactant	and/or	polymer	excipients	[1].	SDNs	can	be	administered	orally	as	solid	formats,	or
resuspended	to	generate	a	nanoparticle	dispersion	for	liquid	oral	or	parenteral	administration	(Figure.	1).	APIs	with	low	aqueous-solubility	represent	ideal	candidates	for	SDN	approaches,	for	which	many	processes	are	available	for
their	manufacture	 [2].	 Importantly,	 SDN	 formation	 does	 not	 involve	 the	 use	 of	 polymer,	 lipid	 or	 inorganic	 nanocarriers,	which	 distinguishes	 this	 approach	 from	many	 other	 nanotechnologies	 being	 investigated	 for	 drug	 delivery
applications.	Because	complex	carrier	systems	are	not	employed,	and	stabilisers	tend	to	be	drawn	from	those	used	in	many	established	medicines	(i.e.	GRAS	or	CDER	listed	excipients	[3]),	SDNs	suffer	less	regulatory	uncertainty	and
achieve	higher	drug-excipient	loading	than	other	approaches.
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Abstract
The	use	of	solid	drug	nanoparticles	(SDN)	has	become	an	established	approach	to	improve	drug	delivery,	supporting	enhancement	of	oral	absorption	and	long-acting	administration	strategies.	A	broad	range	of	SDNs
have	been	successfully	utilised	for	multiple	products	and	several	development	programmes	are	currently	underway	across	different	therapeutic	areas.	With	some	approaches,	a	large	range	of	material	space	is	available	with
diversity	in	physical	characteristics,	excipient	choice	and	pharmacological	behaviour.	The	selection	of	SDN	lead	candidates	is	a	complex	process	including	a	broad	range	of	in	vitro	and	in	vivo	data,	and	a	better	understanding
of	how	physical	characteristics	relate	to	performance	is	required.	Physiologically-based	pharmacokinetic	(PBPK)	modelling	is	based	upon	a	comprehensive	integration	of	experimental	data	into	a	mathematical	description	of
drug	distribution,	allowing	simulation	of	SDN	pharmacokinetics	that	can	be	qualified	in	vivo	prior	to	human	prediction.	This	review	aims	to	provide	a	description	of	how	PBPK	can	find	application	into	the	development	of	SDN.
Integration	of	predictive	PBPK	modelling	into	SDN	development	allows	a	better	understanding	of	the	SDN	dose-response	relationship,	supporting	a	framework	for	rational	optimisation	while	reducing	the	risk	of	failure	in
developing	safe	and	effective	nanomedicines.
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Nanotechnologies	 have	 the	 potential	 to	 generate	 exciting	 advances	 across	 numerous	 fields	 but	 understanding	 short-,	medium-,	 and	 long-term	 safety	 is	 essential	 to	 development	 of	 nanomedicine	 applications.	 As	 for	 any
medicine,	a	 robust	understanding	of	 the	exposure-response	relationship	 is	needed	along	with	a	 thorough	understanding	of	 the	 likely	plasma	and	 tissue	exposure	 in	patients.	Consequently,	understanding	 the	 interactions	between
nanomaterials	and	 the	human	body	 is	essential	 for	efficient	development	of	safe	and	effective	applications	 in	medicine.	The	 investigation	of	nanomedicine	distribution	 is	based	on	a	variety	of	experimental	methods	and	emerging
computer-based	 approaches	 have	 been	 highlighted	 as	 effective	 tools	 to	 streamline	 the	 development	 of	 innovative	 formulations.	 Computational	 models	 to	 simulate	 the	 interaction	 with	 biological	 systems	 represent	 valuable
pharmacological	 tools	to	 facilitate	development	and	regulation,	as	has	already	been	achieved	with	small	molecules.	 Indeed,	 in	silico	modelling	has	already	gained	significant	 traction	for	predicting	pre-clinical	efficacy,	 toxicity	and
distribution	of	small	molecules,	as	well	as	dose-prediction	for	first-in-human	trials	[4,	5].	The	approach	is	also	being	widely	employed	in	the	post-marketing	environment	for	assessing	novel	treatment	strategies,	and	predicting	the
magnitude	of	drug-drug-interactions	or	the	likely	impact	of	pharmacogenetic	variation	[6,	7].	Physiologically-based	pharmacokinetic	(PBPK)	modelling	has	emerged	as	a	powerful	computational	tool	to	simulate	the	distribution	of	small
molecules	and	is	now	being	employed	for	nanoparticle-based	therapeutics.
The	purpose	of	this	review	is	to	summarise	the	existing	data	for	application	of	PBPK	modelling	to	drug	delivery	as	it	relates	to	SDN	development	and	implementation.	Current	gaps	in	knowledge	and	areas	for	further	study	are
also	highlighted.
2.2	Recent	advances	in	solid	drug	nanoparticle	(SDN)	applications
The	 majority	 of	 currently	 clinically	 used	 nanomedicines	 involve	 the	 use	 of	 SDNs	 [8].	 SDNs	 can	 be	 produced	 using	 a	 variety	 of	 approaches	 including	 emulsion-based	 methods,	 nanoprecipitation	 [9],	 or	 high-pressure
homogenisation	 [10],	 but	 the	 most	 commercially	 successful	 approach	 to	 date	 has	 involved	 nanomilling	 [3].	 SDNs	 have	 been	 used	 predominantly	 for	 either	 improved	 oral	 drug	 delivery,	 or	 as	 long-acting	 injectables	 (LAI)	 via
intramuscular	delivery.	One	of	the	most	successful	areas	of	application	has	been	the	improvement	of	oral	bioavailability	of	poorly	water-soluble	APIs	and	this	nanotechnology	has	been	successfully	utilised	for	multiple	products	such	as
Emend®	(aprepitant),	Triglide®	(fenofibrate),	Rapamune®	(sirolimus),	TriCor®	(fenofibrate)	to	name	but	a	few.	SDNs	have	been	highly	successful	for	LAI	strategies,	through	which	therapeutic	or	preventive	plasma	concentrations	of
drugs	are	sustained	for	a	period	of	weeks	to	months,	allowing	infrequent	and	regular	administration	[8].	LAI	formulations	provide	long-term	exposure,	which	may	be	of	particular	benefit	in	chronic	disease	or	for	indications	where
adherence	to	therapy	is	essential	for	desirable	clinical	outcomes.	Indeed,	the	desirability	of	lower	frequency	administration	has	been	consistently	observed	in	patient	attitude	surveys	[11,	12].	Multiple	SDN	development	programmes
are	currently	underway	across	several	therapeutic	areas.	For	example,	the	authors	are	involved	in	several	development	programmes	to	bring	forward	oral	and	LAI	SDN	products	for	treatment	and	prevention	of	infectious	diseases	[13].
3.3	Modelling	and	simulation	approaches	applied	to	SDN	development	and	implementation
Figure	1Fig.	1	Overview	of	solid	drug	nanoparticle	manufacture	and	application.	Different	manufacturing	processes	produce	either	a	liquid	suspension	that	can	be	used	directly	for	liquid	applications,	or	a	dry	powder	that	can	be	filled	directly	into	capsules	or
further	processed	into	tablets.	Suspensions	can	be	further	processed	to	produce	solid	formats,	and	dry	powders	can	be	redispersed	to	form	liquid	medicines.	Parenteral	formats	require	either	production	using	sterile	manufacture,	or	post-sterilisation	(e.g.
irradiation).
alt-text:	Fig.	1
3.1.3.1	Physiologically-based	pharmacokinetic	(PBPK)	modelling
PBPK	modelling	is	based	on	a	detailed	understanding	of	the	processes	underpinning	drug	distribution	and	the	impact	that	SDN	formation	can	have	upon	this	at	the	site	of	administration	[14,	15].	Importantly,	irrespective	of	the
route	of	administration	of	SDNs,	the	nanoparticles	are	thought	to	dissolve	prior	to	or	immediately	on	absorption	to	release	small	molecule	APIs	into	the	systemic	compartment.	Therefore,	the	critical	considerations	for	PBPK	modelling
of	 SDNs	 relate	 to	 the	manner	 in	which	 they	 are	 absorbed	 either	 in	 the	 gastrointestinal	 tract	 or	 from	 the	 intramuscular	 depot	 site,	 and	 once	 absorbed	 PBPK	models	 are	 identical	 to	 those	 for	 small	molecule	 delivery	 (Figure.	 2).
Consequently,	a	specific	representation	of	mechanisms	underpinning	SDN	and	drug	absorption	through	different	routes	of	administration	is	necessary.
PBPK	modelling	requires	that	anatomically	meaningful	compartments	are	defined	which	integrate	specific	properties	of	a	given	organ	or	tissue	(i.e.	blood	flow,	mass,	permeation	limits)	with	drug	characteristics,	to	create	a
mathematical	representation	of	the	human	body	[16].	PBPK	modelling	then	combines	mathematical	equations	to	describe	the	anatomical,	physiological	and	molecular	processes	regulating	pharmacokinetics	with	relative	in	vitro	data	to
simulate	and	predict	distribution	of	the	drug.	Experimental	in	vitro	data	such	drug	dissolution,	apparent	permeability	through	the	intestinal	barrier,	or	interaction	with	the	intestinal	mucus	can	be	integrated	in	a	mechanistic	description
of	oral	absorption	to	evaluate	bioavailability	[17].	Similarly,	in	vitro	systems	can	be	used	to	capture	drug	release	rates	from	the	formulation	for	applications	in	LAI	[18,	19].	Therefore,	the	impact	of	SDN	formation	on	these	mechanisms
and	robust	in	vitro	systems	to	capture	the	differences	are	prerequisite	to	accurate	modelling.
Once	absorbed,	drug	distribution	 in	 tissues	and	organs	 is	 simulated	 considering	 regional	blood	and	 lymphatic	 flows,	 transporter	 activity	 and	drug	physicochemical	properties	 influencing	 tissue	 to	plasma	 ratio.	Processes
mediating	drug	degradation	and	elimination	in	tissues	such	as	the	liver	and	kidney	can	be	investigated	in	vitro	through	standardised	approaches	to	provide	an	estimate	of	apparent	clearance,	which	following	integration	with	data	on
enzyme	expression	 in	patient	and	organ	size,	can	support	a	quantitative	prediction	of	 total	clearance	[20].	All	 the	above	pharmacokinetic	processes	are	characterised	by	 intra-	and	 inter-patient	variability	which	can	be	accurately
represented	through	a	mathematical	description	of	environmental	and	patient-specific	factors	affecting	drug	distribution	[21].	Firstly,	variability	in	anthropometric,	anatomical,	physiological	and	molecular	characteristics	of	the	patient
population	have	been	extensively	described	and	this	set	of	equations	constitute	an	essential	element	in	the	design	of	PBPK	models	[21].	Additionally,	environmental	factors	such	as	food	and	concomitant	drugs	can	influence	relevant
Figure	2Fig.	2	Graphical	representation	of	a	physiologically	based	pharmacokinetic	model.	Experimental	data	are	integrated	in	to	a	mechanistic	description	of	drug	distribution	to	support	a	simulation	of	pharmacokinetics	in	virtual	individuals.	Relevant	routes	of	administration	(e.g.
oral	and	long	acting	IM)	can	be	represented	considering	formulation	specific	characteristics.	Grey	lines	represent	the	lymphatic	circulation.
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drug	distribution	processes	and	dedicated	experimental	and	computational	approaches	can	allow	robust	prediction	of	their	effect	on	intra-	and	inter-patient	variability.	Overall,	it	is	therefore	possible	to	simulate	a	virtual	but	realistic
population	of	patients	and	to	allow	the	simulation	of	pre-clinical	and	clinical	studies	[21].	Importantly,	because	small	molecules	predominate	systemically	after	administration	of	SDNs,	base	models	can	be	accurately	qualified	post-
absorption	with	available	clinical	or	preclinical	data	even	before	SDNs	are	developed.	Therefore,	for	SDNs	everything	other	than	drug	absorption	can	be	qualified	prior	to	simulation,	which	dramatically	reduces	uncertainty	compared
to	applications	in	nanocarrier	medicines	where	the	carrier	is	introduced	systemically	to	specifically	modulate	the	distribution	and	clearance.	Nanomaterials	that	reach	the	systemic	circulation	as	intact	particles	are	characterised	by
fundamentally	different	biodistribution,	which	is	mediated	by	a	broad	variety	of	processes	such	as	penetration	through	the	vascular	fenestration	or	uptake	by	phagocytic	cells.	Modelling	approaches	for	nanoformulations	were	recently
summarised	in	a	review	with	specific	focus	on	challenges	in	model	development,	validation	and	regulatory	priorities	[22].
PBPK	models	 have	 relevant	 limitations	 and	 a	 full	 understanding	 of	 these	 implications	 is	 critical	 to	meaningful	 application	 of	 this	 computational	 approach.	 The	 reliability	 of	 PBPK	models	 is	 strictly	 related	 to	 a	 detailed
description	of	processes	 regulating	drug	distribution,	and	consequently	a	partial	description	of	 relevant	DMPK	mechanisms	will	 result	 in	 limited	accuracy	 for	predictions.	Absorption	can	also	be	mediated	by	phagocytic	cells	and
subsequently	nanomaterials	can	reach	the	lymphatic	circulation	resulting	in	different	pharmacokinetic	patterns.	The	in	vitro	approaches	used	to	capture	this	are	therefore	pivotal,	influencing	the	quality	of	pharmacokinetic	predictions.
Thus,	a	full	qualification	of	the	experimental	methodology	is	essential	to	support	a	successful	integration	of	in	vitro	data	into	PBPK	models.		Moreover,	a	suboptimal	description	of	patient	characteristics	can	lead	to	a	poor	prediction	of
pharmacokinetic	differences	in	the	population	of	interest,	limiting	opportunities	for	application	(e.g.	dose	stratification).
Modelling	of	drug	pharmacokinetics	is	increasingly	used	by	both	academic	groups	and	pharmaceutical	industries	and	numerous	computational	platforms	have	been	described.	Various	commercial	platforms	are	available	(i.e.
Simcyp,	GastroPLus,	etc.)	which	provide	comprehensive	packages	for	simulations	with	user-friendly	 interfaces.	PBPK	models	can	also	be	developed	by	users	with	more	flexible	computational	platforms	(i.e.	MATLAB,	R,	etc.)	which
require	a	more	detailed	understanding	of	model	assumptions	and	structure,	but	provide	greater	opportunities	for	exploring	novel	mechanisms.
3.2.3.2	Complimentary	computational	approaches
Other	computational	techniques	can	be	integrated	with	PBPK	modelling	in	order	to	fill	gaps	needed	for	simulation.	For	example,	quantitative	structure–activity	relationship	(QSAR)	studies	are	theoretical	models	that	relate	the
structure	of	molecules	to	their	pharmacological	properties	(distribution	patterns,	toxicity,	etc.).	QSARs	are	quantitative	relationships	based	on	data	analysis	approaches	such	as	multivariate	linear	regression	and	random	forest,	aiming
to	identify	molecular	descriptors	predicting	biological	activity	[23].	The	molecular	descriptors	can	be	the	structural,	geometrical	and	physicochemical	properties	of	the	whole	molecule	or	isolated	functional	groups,	and	QSAR	models
can	be	developed	and	validated	through	multiple	training	sets	of	well	characterised	molecules.	The	validated	model	can	then	be	applied	to	novel,	uncharacterised	molecules	providing	a	quantitative	estimate	of	the	variable	of	interest.
The	application	of	QSAR	to	pharmacokinetics	provides	 the	opportunity	 to	estimate	key	paramenters	 for	 the	prediction	of	distribution	 (Volume	of	distribution,	systemic	clearance,	protein	binding,	etc.)	and	 the	 integration	of	QSAR
models	into	a	PBPK	framework	supporting	the	simulation	of	pharmacokinetic	profiles	for	candidate	drugs	and	therefore	allowing	the	selection	of	candidates	with	optimal	pharmacokinetic	potential.	It	is	important	to	recognise	that	such
approaches	 themselves	have	 limitations	 that	may	 increase	uncertainty	 in	model	prediction.	However,	 this	can	provide	a	useful	starting	point	 for	model	development	 in	 the	absence	of	empirical	experimental	data,	and	since	SDNs
release	dissolved	drug	systemically	the	field	can	draw	upon	a	wealth	of	QSAR	data	that	has	been	generated	over	several	decades.
4.4	Applications	of	PBPK	modelling
4.1.4.1	The	application	of	PBPK	modelling	to	oral	SDN	development
Although	pharmacokinetic	modelling	has	only	been	recently	applied	in	the	nanomedicine	field,	several	paradigms	exist	as	examples	for	integration	of	PBPK	in	the	rational	design	and	development	of	SDNs.	Importantly,	this	has
been	rapidly	possible	due	to	a	comprehensive	qualification	and	validation	of	existing	modelling	approaches	for	small	molecules.	For	example,	the	authors	recently	demonstrated	how	a	predictive	computational	approach	was	able	to
deliver	a	very	precise	simulation	of	genetically-influenced	differences	in	pharmacokinetic	exposure	for	the	antiretroviral	efavirenz	[24].	Moreover,	an	a	priori	PBPK	prediction	of	the	pharmacokinetic	consequences	of	efavirenz	dose
reduction	was	validated	across	relevant	pharmacokinetic	parameters	on	completion	of	the	pharmacokinetic	sub-study	imbedded	within	a	phase	III	clinical	trial	[24].
The	authors	have	also	applied	PBPK	to	prediction	of	pharmacokinetics	after	oral	delivery	of	SDNs	manufactured	with	poorly	soluble	drugs	with	low	permeability.	SDNs	are	likely	to	adhere	to	the	intestinal	mucus	creating	a	high
concentration	in	situ	and	therefore	favouring	absorption	by	saturating	active	transporters	and/or	accessing	particle-specific	mechanisms.	As	described	through	the	use	of	FRET	dyes	within	dual-component	SDNs	for	the	characterisation
of	cellular	permeability	through	intestinal	cell	monolayers,	movement	of	intact	dual-component	particles	was	reported,	suggesting	a	paracellular	mechanism	for	enhanced	absorption	[1].	Overall	SDNs	can	therefore	improve	absorption
of	APIs	through	multiple	mechanisms	and	experimentally	this	effect	has	been	clearly	described	through	traditional	high	throughput	methodology.	In	multiple	reports,	increased	apparent	permeability	through	Caco-2	cell	monolayers	(a
well	standardised	approach	to	investigate	oral	absorption	of	drugs)	has	been	described	for	SDNs	compared	to	solutions	of	APIs		[1,	24].	 Interestingly,	not	all	SDNs	have	been	shown	to	result	 in	higher	absorption	rate	 in	vitro,	with
several	SDN	formulations	exhibiting	lower	apparent	permeability	compared	to	controls.	This	highlights	the	importance	of	SDN	physical	properties	and	excipient	choice	in	mediating	pharmacological	benefits,	and	SDNs	with	higher	z-
average	diameters	were	demonstrated	to	have	better	permeability	and	simulated	pharmacokinetics	[24].
Integrating	the	experimental	analysis	of	intestinal	permeability	into	a	PBPK	model	is	essential	to	fully	understand	SDN	potential	and	help	the	translation	of	valuable	candidates.	Physiological	and	molecular	processes	can	be
successfully	represented	in	PBPK	modelling,	supporting	a	computer-based	simulation	of	the	absorption	of	SDNs	and	therefore	a	quantitative	prediction	of	the	pharmacokinetic	benefits	resulting	from	the	administration	of	SDNs.	If
models	are	successfully	qualified,	SDN	pharmacological	potential	can	be	evaluated	through	the	integration	of	experimental	data	into	a	mathematical	representation	of	intestinal	absorption,	drug	distribution	and	elimination	in	virtual
patients	or	pre-clinical	species.	This	strategy	has	recently	been	applied	to	rationalise	the	selection	of	optimal	SDN	candidates	and	simulated	pharmacokinetics	resulting	from	SDN	administration	has	been	confirmed	through	clinical
studies.	PBPK	modelling	of	experimental	 in	vitro	data	predicted	an	 increase	 in	bioavailability	 for	an	optimised	efavirenz	SDN	to	nearly	100%	and	a	 theoretical	dose	 reduction	of	50%	to	achieve	similar	exposure	 to	 the	 traditional
clinically	used	formulation	[25].	Importantly,	this	prediction	was	subsequently	confirmed	in	a	preliminary	first-in-human	healthy	volunteer	clinical	trial	[13].
4.2.4.2	The	application	of	PBPK	modelling	to	parenteral	SDN	development
Computational	pharmacokinetic	modelling	can	also	provide	a	rational	framework	for	the	selection	of	candidate	APIs	for	LAI	SDN	development.	Moreover,	the	approach	can	aid	identification	of	minimal	dose	requirements	and
optimal	formulation	characteristics	to	support	sustained	exposure	over	the	dosing	interval.	Multiple	therapeutic	areas	are	being	explored	for	LAI	development,	and	these	are	characterised	by	a	broad	spectrum	of	pharmacological
options	and	in	many	cases	there	is	a	need	for	combination	therapies.	Consequently,	rationalising	administration	strategies	requires	consideration	of	multiple	complex	formulation,	pharmacokinetic	and	pharmacodynamic	priorities.
Computational	modelling	provides	the	opportunity	to	simulate	relevant	scenarios	and	therefore	support	identification	of	strategies	with	a	higher	chance	of	success.	For	example,	HIV	treatment	is	based	on	the	combination	of	multiple
agents	and	current	treatment	and	prevention	strategies	are	almost	exclusively	based	upon	oral	administration.	Notwithstanding,	LAI	SDN	formulations	have	recently	been	developed	with	rigorous	pre-clinical	and	clinical	testing	[26],
and	rilpivirine	LA	and	cabotegravir	LA	have	shown	great	promise	for	treatment	and	pre-exposure	prophylaxis	[27].	It	is	widely	expected	that	the	coming	years	will	see	a	proliferation	of	LAI	SDN	medicines	for	HIV,	but	the	selection	of
drug	 candidate	 for	 future	 development	 is	 extremely	 complex.	 Recently,	 the	 authors	 reported	 use	 of	 a	 PBPK	 model	 to	 simulate	 theoretical	 pharmacokinetics	 resulting	 from	 LAI	 administration	 of	 experimental	 and	 established
antiretroviral	drugs	to	identify	suitable	API	candidates	and	prerequisite	formulation	behaviours	[14].
Similarly,	 for	 other	 disease	 areas,	 LAI	 strategies	 could	 greatly	 simplify	 drug	 administration	 especially	 when	 Directly	 Observed	 Therapy	 (DOT)	 is	 necessary	 such	 as	 is	 the	 case	 for	 tuberculosis	 [28].	 Recently,	 modelling
simulations	have	been	used	to	explore	if	SDNs	can	support	LAI	strategies	for	the	prevention	and	treatment	of	tuberculosis	infection,	helping	a	more	rational	selection	of	established	and	experimental	APIs	for	future	research	[29].
Minimal	dose	and	dosing	frequency	where	also	simulated	to	evaluate	if	LAI	administration	could	be	implemented	within	the	constraints	of	existing	treatment	protocols.
An	additional	complication	is	the	limited	clinical	implementation	of	this	long	acting	strategies	for	vulnerable	patients,	when	multiple	logistical	and	ethical	barrier	can	complicate	clinical	investigations.	Physiological	changes	and
altered	expression	of	drug	metabolism	enzymes	in	elderly	and	pregnant	women	can	influence	drug	pharmacokinetics,	efficacy	and	toxicity	[30,	31].	Vulnerable	patients	have	higher	incidence	of	co-morbidities	and	therefore	complex
polypharmacy.	In	paediatricpediatric	patients,	growth	consist	of	a	continuum	of	biologic	events	and	the	development	of	relevant	metabolism	enzymes	is	not	linear,	complicating	the	investigation	of	PK	especially	in	very	young	patients
[32,	33].	Additionally,	comorbidities	can	impact	molecular	and	physiological	factors	influencing	drug	distribution.	The	mathematical	description	of	these	effects	has	been	successfully	implemented	in	PBPK	models	and	therefore	further
supports	the	application	of	computational	approaches.	Overall,	for	vulnerable	patients	the	design	of	clinical	investigations	of	novel	formulations	is	extremely	complex	and	consequently	this	is	comprehensively	investigated	in	a	very
limited	number	of	cases	[34].	Characteristics	of	specific	sub-populations	of	patients	can	be	represented	mathematically	and	successfully	integrated	in	PBPK	models,	allowing	the	prediction	of	pharmacokinetics	in	vulnerable	populations
and	therefore	the	simulation	of	innovative	administration	strategies	[35].	The	application	of	long	acting	administrations	for	special	population	represents	an	extremely	valuable	strategy	due	to	particularly	poor	adherence	patterns	for
patients	such	as	neonates	and	children	[36].	Existing	daily	oral	 formulations	for	children	are	often	 liquid	based	on	different	solvents,	with	poor	palatability	and	dosing	can	be	complex	[36].	PBPK	models	can	be	applied	to	 identify
suitable	dosing	strategy	for	SDN	long	acting	administration	in	children.	For	HIV	treatment	a	recent	publication	explored	multiple	options	for	dosing	in	pediatric	children	based	on	WHO	weight	bands,	with	the	overall	aim	of	achieving
similar	exposure	to	adults	treated	with	validated	regimes	[35].	The	identified	dosing	strategies	are	a	rational	platform	for	future	clinical	investigations	and	therefore	can	simplify	the	dose	finding	process.
It	is	important	to	recognise	that	the	ambition	of	the	LAI	projects	described	above	were	to	inform	future	SDN	development	by	assessing	what	is	feasible	in	an	API-specific	manner,	and	what	would	be	required	from	an	SDN
formulation	to	achieve	it.	As	such,	this	work	was	not	conducted	with	data	available	with	SDN	formulations,	and	is	therefore	pre-emptive	in	nature.	This	is	partially	due	to	the	current	paucity	of	knowledge	relating	to	the	in	vitro	and	in
vivo	 behaviour	 of	SDN	LAI	 formulations	 [8].	Recently,	 the	 authors	 reported	 an	LAI	SDN	 formulation	 of	 atovaquone,	which	was	 able	 to	 protect	mice	 from	exposure	 to	plasmodium	berghei	 sporozoites	 for	 28 days	 following	 a	 single
intramuscular	administration	[37].	Importantly,	several	formulations	were	developed	as	part	of	this	programme,	providing	critical	formulation,	pharmacokinetic	and	pharmacodynamic	data	that	can	be	employed	for	future	PBPK	model
refinement.
4.3.4.3	A	role	for	PBPK	in	reducing	the	number	of	animals	used	in	SDN	development
A	strategised	integration	of	PBPK	modelling	in	SDN	and	more	broadly	in	nanomedicine	development	has	the	potential	to	effectively	reduce	the	use	of	preclinical	animal-based	models.		It	is	estimated	that	worldwide	more	than
one	 thousand	 companies	 are	 currently	 developing	 nanotechnology	 applications	 in	 medicine	 and	 consequently	 had,	 are	 or	 will	 use	 preclinical	 animal	 models	 to	 investigate	 nanoparticle	 pharmacokinetics	 and	 distribution.	 More
widespread	application	of	predictive	PBPK	modelling	in	this	type	of	investigation	has	the	potential	to	support	a	more	informed	selection	of	which	species	to	study	as	well	as	an	effective	quantification	of	animals	needed	to	achieve
sufficient	 accuracy.	 Therefore,	 PBPK	modelling	 has	 the	 potential	 to	 greatly	 reduce	 the	 overall	 number	 of	 animals	 used	 in	 nanomedicine	 development.	 Computational	 approaches	 provide	 a	 quantitative	 prediction	 of	 nanoparticle
distribution	 in	 tissues	 that	would	 require	 validation	 in	 a	 few	groups	 of	 animals,	 supporting	 the	Replacement,	Reduction	 and	Refinement	 (3Rs)	 of	 preclinical	 species	 in	 research	 and	development.	 There	 are	 barriers	 to	 achieving
widespread	uptake	of	PBPK	modelling	in	the	nanomedicine	community,	which	are	driven	by	model	complexity	and	current	gaps	in	mechanistic	knowledge.	However,	fuelled	by	the	needs	highlighted	by	regulatory	authorities,	significant
adoption	is	expected	in	the	coming	years.
5.5	Summary	and	conclusions
Modelling	approaches	for	nanoparticle	applications	are	currently	in	their	infancy	compared	to	small	molecules,	and	the	processes	regulating	distribution	of	nanoparticles	are	known	to	be	substantially	different.	PBPK	models
can	assist	in	answering	questions	that	cannot	otherwise	be	examined	in	pre-clinical	development	and	clinical	studies	as	well	as	streamline	the	regulatory	process.	They	provide	the	opportunity	for	rational	design	of	nanomedicines,
identifying	strategies	to	maximise	the	efficacy	and	safety	of	novel	technologies.	A	mechanistic	understanding	of	the	molecular	and	physiological	events	that	define	nanoparticle	distribution	can	have	a	beneficial	impact	on	development
of	novel	nanoparticle	assessment	strategies	and	on	the	characterisation	of	toxicological	risk.	There	is	a	clear	need	for	increased	application	of	such	computational	approaches	to	nanomedicine	development	and	regulatory	process,
which	is	underpinned	by	a	more	thorough	understanding	of	the	factors	influencing	nanoparticle	behaviour.	This	is	further	strengthened	by	how	the	broad	variety	of	materials	used	for	synthesis	and	their	potential	combinations	define
an	inexhaustive	list	of	delivery	strategies	available	across	sectors.
Computational	pharmacokinetic	modelling	has	potential	to	provide	an	extremely	valuable	tool	for	the	design	of	nanomaterials.	More	specifically,	PBPK	modelling	has	been	proven	to	help	the	optimisation	of	SDN	for	multiple
administration	strategies	and	different	disease	areas.	SDNs	are	a	nanotechnology	with	several	applications	in	the	enhancement	of	oral	bioavailability	and	sustained	release	of	APIs,	but	their	optimisation	is	a	complex	process	based	on	a
broad	range	of	 in	vitro	and	in	vivo	data.	Frequently,	SDN	synthesis	generates	a	high	number	of	potential	candidates	and	the	direct	testing	of	all	nanoparticles	 in	vivo	would	have	multiple	ethical	and	 logistical	barriers.	A	detailed
understanding	of	the	processes	underpinning	SDN	pharmacology	combined	with	well	characterised	in	vitro	data	and	predictive	computational	models,	will	allow	a	rational	selection	of	valuable	formulations	so	that	those	without	value
can	be	killed	early	in	development.	Integrated	approaches	in	silico,	in	vitro	and	pre-clinical	in	vivo	methodologies	will	enhance	essential	knowledge	of	SDN	pharmacology	while	defining	an	optimal	framework	for	the	identification	of
nanoformulations	with	higher	pharmacological	potential.
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